Nuvectis Pharma (NVCT) analyst forecast and price target
Analyst forecast
Consensus of 5 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $39.00 | Sep 24, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | — | Aug 24, 2026 |
| Roth Capital | Maintained | Buy | $33.00 from $20.00 | Jul 6, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $39.00 from $13.00 | Jun 22, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $13.00 from $10.00 | Jun 12, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 from $15.00 | Aug 4, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $15.00 from $11.00 | Apr 30, 2025 |
| Maxim Group | Initiated Coverage | Buy | $17.00 | Apr 2, 2025 |
| Laidlaw & Co. | Initiated Coverage | Buy | $19.00 | Mar 17, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $11.00 from $21.00 | Feb 25, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $21.00 | Aug 6, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $21.00 | May 8, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $21.00 | Sep 15, 2023 |
Frequently asked questions
Is NVCT a buy, sell, or hold?
Analysts covering Nuvectis Pharma currently average a Buy rating: 5 buy, 0 hold and 0 sell, from 5 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on NVCT?
On Sep 24, 2026, HC Wainwright & Co. maintained Nuvectis Pharma at Buy with a price target of $39.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.